AtHO1 (HY1) encodes heme oxygenase-1 in Arabidopsis, catalyzing cleavage of heme to biliverdin with the release of iron and carbon monoxide (CO). Our previous study showed that CO as an endogenous component is able to improve plant adaptation to iron deficiency. Here, we performed a genetic study to identify further the putative role of AtHO1 in the iron deficiency response. Iron deficiency induced AtHO1 expression at the transcriptional and translational levels. Evidence has been provided that overexpression of AtHO1 could confer plant tolerance to iron deficiency by improving expression of AtFIT, AtFRO2 and AtIRT1, the activity of ferric-chelate reductase (FCR) and iron accumulation. In contrast, RNA interference with AtHO1 expression in 35S::AntiHO1 plants and the AtHO1 loss-of-function (hy1 mutant) resulted in adverse phenotypes. In 35S::AtHO1 transgenic lines, a higher level of CO and water-soluble iron, and a lower level of heme were identified, suggesting that AtHO1-regulated iron homeostasis was possibly through the catabolism of heme to produce CO and free iron. Because nitric oxide (NO) is known to regulate iron homeostasis in plants, the connection between AtHO1 expression and NO action was examined. AtHO1-overexpressing plants generated more NO, whereas knock-down of AtHO1 expression reduced the level of NO in plants. The NO scavenger cPTIO [2-(4-carboxy-2-phenyl)-4,4,5,5-tetramethylini dazoline-1-oxyl-3-oxide] caused a decrease in AtHO1-induced FCR activity. Under both iron-sufficient and -deficient conditions, administration of the NO donor sodium nitroprusside induced FCR activity in the hy1 plants. These results suggest that AtHO1 is involved in iron homeostasis in an NO-dependent manner.
This study aims to determine which cell death modes contribute most in the progression of cirrhosis and acute-on-chronic liver failure (ACLF), and to investigate whether Yes associated protein (YAP) affects the disease process by regulating cell death. 30C57BL/6 male mice were divided into five groups: control, carbon tetrachloride (CCl4)-induced liver fibrosis model, CCl4+verteporfin, CCl4+lipopolysaccharides (LPS) combined with the D-(+)-Galactosamine (LPS/D-GalN)-induced ACLF model, and ACLF + verteporfin. Patients with chronic hepatitis B (CHB), hepatitis B virus (HBV) related liver cirrhosis or ACLF were enrolled. Histology, immunohistochemistry, transmission electron microscopy, Western blot and ELISA were conducted to assess the roles of YAP and cell death in liver cirrhosis and ACLF, and to explore the effect of YAP inhibition on cell deaths. YAP was markedly increased in mice with liver fibrosis and ACLF, along with ferroptosis and necroptosis. Furthermore, YAP inhibition significantly suppressed fibrosis in CCl4-mediated liver fibrosis and ACLF-associated liver injury. Notably, CCl4 induced up-regulation of ACSL4 and RIPK3 and down-regulation of SLC7A11, key factors in ferroptosis and necroptosis. This was significantly abrogated by verteporfin treatment. Similar changes in ferroptosis and necroptosis were found in ACLF and ACLF + verteporfin groups. Consistent with the above findings in mice, we found that plasma YAP levels were gradually increased with the development of HBV-related liver fibrosis and ACLF. Ferroptosis and necroptosis are involved in the development of liver cirrhosis and ACLF. Inhibition of YAP improved liver fibrosis and liver damage in ACLF through a reduction in ferroptosis and necroptosis. Our findings may help better understanding the role of YAP in liver fibrosis and ACLF.
29 April 2022 in Canadian Journal of Gastroenterology and Hepatology
Objective. To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods. The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. Results. Four genotypes and six subtypes were identified as follows: 1b (1187, 54.90%), 2a (790, 36.54%), 3a/b (134, 6.20%), 6a/n (44, 2.04%), mixed genotypes (2a-6a or 2a-3a) (7, 0.32%). Overall, 99.01% patients achieved SVR12, while 98.43% achieved SVR24. All patients treated with elbasvir/grazoprevir (EBR/GZR), sofosbuvir/velpatasvir ± ribavirin (SOF/VEL ± RBV), and SOF/ledipasvir (LDV) achieved SVR12 or SVR24; 92.86% SVR12 and 95.83% SVR24 were observed in patients using SOF + RBV. SVR12 was higher in noncirrhosis versus compensated cirrhosis patients (100% vs. 97.09%, ). No severe drug-related adverse event was observed. Conclusions. Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile.
Aim: To explore the predictive value of plasma YAP1 for esophageal varices (EV) and high-risk EV (HRV) in patients with liver cirrhosis. Materials & methods: A total of 208 patients with liver cirr...